|
WO2021030482A1
|
|
Improved formulations for immune cells
|
|
WO2020123766A1
|
|
Psca car-t cells
|
|
WO2020092440A1
|
|
T cells with suicide switch
|
|
US2021107966A1
|
|
Natural killer cell products and methods
|
|
EP3728189A1
|
|
Multimeric piperidine derivatives
|
|
WO2019113509A2
|
|
Methods for enhancing and maintaining car-t cell efficacy
|
|
WO2018208849A1
|
|
Methods to augment or alter signal transduction
|
|
AU2016370470A1
|
|
Dual controls for therapeutic cell activation or elimination
|
|
EP3234145A2
|
|
Methods for controlled activation or elimination of therapeutic cells
|
|
AU2015362748A1
|
|
Methods for controlled elimination of therapeutic cells
|
|
CA2959168A1
|
|
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
|
AU2015226960A1
|
|
Caspase polypeptides having modified activity and uses thereof
|
|
EP3104866A1
|
|
Methods for activating t cells using an inducible chimeric polypeptide
|
|
AU2014253529A1
|
|
Method for treating solid tumors
|
|
EP3569253A1
|
|
Methods for inducing partial apoptosis using caspase polypeptides
|
|
CN105209065A
|
|
Methods for controlling t cell proliferation
|
|
US2014255360A1
|
|
Modified caspase polypeptides and uses thereof
|
|
WO2011146862A1
|
|
Methods for inducing selective apoptosis
|
|
WO2007137300A2
|
|
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
